1 BTC
=
- USD
Humacyte, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Humacyte, Inc. Common Stock
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Market Statistics
Trading Metrics
How to Buy HUMA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy HUMA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesHumacyte announced Q1 2026 financial results showing Symvess product revenue of $0.5M (up from $0.1M in Q1 2025) with 29 units sold. The company appointed industry veterans James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer to accelerate commercialization. Key upcoming milestone includes Phase 3 hemodialysis trial interim results on June 11, 2026. The company also received a $1.475M purchase commitment from Saudi Arabia and DoD funding for bioengineered blood vessels. Despite restructuring that reduced headcount by 25%, Humacyte expects $14.3M in cost savings for the remainder of 2026.
Humacyte announced that renowned vascular surgeon Dr. Todd E. Rasmussen has joined as Chief Surgical Officer. Dr. Rasmussen brings 28 years of military medical experience and current Mayo Clinic faculty status to support clinical adoption of Symvess and advance the company's bioengineered tissue pipeline toward regulatory approval.
Humacyte reported $2.0 million in total revenues for 2025 with 61 Symvess units sold. The company announced a $1.475 million purchase commitment from Saudi Arabia, FDA submission in Israel, and U.S. Department of Defense funding authorization. Key upcoming milestone includes top-line interim results from the V012 Phase 3 hemodialysis study expected in Q2 2026, with planned BLA filing in H2 2026. The company ended 2025 with $50.5 million in cash and secured a $77.5 million credit facility.
Humacyte published long-term clinical data showing Symvess, a bioengineered vascular conduit, maintained structural integrity over 36 months with 92.9% infection-free rates, 82.5% limb salvage at 24 months, and no unprovoked structural failures in extremity arterial trauma patients. The results represent the first prospective long-term data for an off-the-shelf biologic conduit in traumatic arterial repair where autologous vein grafts are not feasible.
